A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Description

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Conditions

Breast Cancer, Early Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Condition
Breast Cancer, Early Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

Research Site, Birmingham, Alabama, United States, 35205

Dothan

Research Site, Dothan, Alabama, United States, 36303

Anchorage

Research Site, Anchorage, Alaska, United States, 99508

Chandler

Research Site, Chandler, Arizona, United States, 85224

Hot Springs National Park

Research Site, Hot Springs National Park, Arkansas, United States, 71913

Anaheim

Research Site, Anaheim, California, United States, 92801

Beverly Hills

Research Site, Beverly Hills, California, United States, 90211

Concord

Research Site, Concord, California, United States, 94520

Corona

Research Site, Corona, California, United States, 92882

Fountain Valley

Research Site, Fountain Valley, California, United States, 92708

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women and Men, ≥18 years at the time of screening (or per national guidelines)
  • * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol.
  • * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy
  • * Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor)
  • * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
  • * Adequate organ and marrow function
  • * Inoperable locally advanced or metastatic breast cancer
  • * Pathological complete response following treatment with neoadjuvant therapy
  • * History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered at very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
  • * Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance
  • * Known LVEF \<50% with heart failure NYHA Grade ≥2.
  • * Mean resting QTcF interval \>480 ms at screening
  • * Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions
  • * Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors (eg, denosumab)
  • * Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant
  • * Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding
  • * Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists, that would preclude the patient from receiving any LHRH agonist

Ages Eligible for Study

18 Years to 130 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AstraZeneca,

Study Record Dates

2036-05-29